We are pleased to announce that Mr Nigel Lange has been appointed as Chief Executive Officer and Managing Director of OncoSil Medical

“I am excited by the opportunity to lead OncoSil Medical as it transitions into a commercial-stage medical device company. Having joined 8 months ago, I truly believe that the Company is set for an exciting future, with an impressive product that addresses such an important unmet medical need.” Mr Nigel Lange

The OncoSil^TM System is approved in several jurisdictions

The OncoSil^TM System is currently approved in Singapore, Malaysia and Switzerland. The device is registered in New Zealand and it also has received CE Marking approval from the British Standards Institute, providing marketing authorisation in both the EU and the UK.¹

REFERENCE 1. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020. Breakthrough Device Designation.

OncoSil^TM is our breakthrough^† device

†The OncoSil^TM device has been designated a breakthrough device in both the United States (FDA) and Europe (BSI)^1,2.

REFERENCES 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. 2. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.

WB00-AU-0121